Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03843775 · ClinicalTrials.gov registry record · Phase 1
A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers
A Phase 1 study of Advanced BRAF Mutant Cancers, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 4
- Study locations
NCT03843775 is a Phase 1 study of Advanced BRAF Mutant Cancers that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 17 participants. The trial reports 4 study locations across 2 states.
The verdict
NCT03843775, a Phase 1 study of Advanced BRAF Mutant Cancers, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this trial is to test the safety and efficacy of an innovative combination aimed to more profoundly inhibit ERK signaling in tumors.
Conditions Studied
Interventions
- DRUG Binimetinib
- DRUG Encorafenib
Study Locations (4)
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk (Limited protocol activity) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-02-14 |
| Est. Completion | 2023-09-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03843775
The ClinicalTrials.gov registry entry for NCT03843775 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced BRAF Mutant Cancers appearing as the primary indexed condition, and to 2 interventions - of which Binimetinib is the first listed.
NCT03843775 reports 4 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT03843775 about?
NCT03843775 is a clinical study titled "A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers". The goal of this trial is to test the safety and efficacy of an innovative combination aimed to more profoundly inhibit ERK signaling in tumors.
What is the current status of trial NCT03843775?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2019-02-14. Estimated completion is 2023-09-02.
What conditions does trial NCT03843775 study?
This clinical trial studies the following conditions: Advanced BRAF Mutant Cancers.
What interventions are being tested in trial NCT03843775?
The interventions under investigation include: Binimetinib (DRUG), Encorafenib (DRUG).
Who is sponsoring clinical trial NCT03843775?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03843775 being conducted?
This trial has 4 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.